BerGenBio to Present at the Carnegie Nordic Healthcare Conference
BERGEN, Norway, March 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at the Carnegie Nordic Healthcare Conference in Stockholm, Sweden, today March 16, 2023, at 1:45 pm CET. The presentation will be made available on the Company website in the Investor/presentations section at time of presentation: www.bergenbio.com/investors/presentations/ -End- Contacts